Novartis Chairman Stresses Need for R&D Investment

Novartis needs to continue investing in research in order to develop new drugs that national health-care systems are willing pay for, a task that gets harder as generic versions of older medicines become available, according to the company’s chairman.

Leave a Reply

Your email address will not be published. Required fields are marked *